Physician profile
Jonathan Spivack
NPI 1497790513
$4,560.69
in general payments reported to CMS, 2019-2025
15 companies · $2,385 in 2025
The $2,385 reported for 2025 was more than what 75% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $122 · 2020: $16.92 · 2021: $107 · 2022: $523 · 2023: $547 · 2024: $860 · 2025: $2,385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,792.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,792.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,144.14 | 2021-2025 | Ubrelvy, Qulipta |
| Pfizer INC. | $1,297.01 | 2020-2025 | |
| Livanova USA, INC. | $320.57 | 2021-2023 | Vns Therapy Sentiva Model 1000 Generator |
| Amgen INC. | $215.39 | 2024-2025 | Uplizna |
| Genzyme Corporation | $134.37 | 2022-2025 | |
| Emd Serono, INC. | $115.86 | 2024 | Mavenclad |
| Lilly USA, LLC | $107.78 | 2019-2024 | Emgality |
| Biohaven Pharmaceuticals, INC. | $57.66 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $46.64 | 2022 | |
| Argenx US, INC. | $29.32 | 2023 | Vyvgart Hytrulo |
| Banner Life Sciences, LLC | $26.42 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $18.61 | 2019 | |
| Allergan, INC. | $16.15 | 2019 | |
| Catalyst Pharmaceuticals, INC. | $15.72 | 2021 | |
| Ucb, INC. | $15.05 | 2023 | Briviact |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Spivack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.